Abstract
The renin angiotensin aldosterone system (RAAS) inhibitors induce an incomplete blockade of the system at different steps. Recently, the dual RAAS therapy is emerging in clinical practice, although there is a lack of evidence on safety and efficacy for this combination in several cardiovascular diseases. In this review, we evaluated the advantages and disadvantages of dual RAAS blockade in hypertension, proteinuric renal disease, heart failure and ischaemic heart disease. The role of DRIs in combination with ACEI or ARBs is promising, but still needs further studies. On the basis of the clinical outcomes and safety data the recommendations guidelines have not confirmed indications to dual RAAS blockade in essential hypertension treatment, heart failure and ischemic heart disease. Only proteinuric nephropaties and resistant hypertension may represent possible indications to dual RAAS blockade. Actually, rational combinations of either an ACEI or ARB or DRI with other classes of antihypertensives offer best solutions.
Keywords: Renin-angiotensin-aldosterone system, hypertension, heart failure, proteinuria, RAAS therapy, cardiovascular diseases, ischaemic heart disease, antihypertensives, nephropaties, aliskiren
Current Pharmaceutical Design
Title: Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Volume: 18 Issue: 7
Author(s): Franco Veglio, Elisabetta Puglisi, Alberto Milan and Paolo Mulatero
Affiliation:
Keywords: Renin-angiotensin-aldosterone system, hypertension, heart failure, proteinuria, RAAS therapy, cardiovascular diseases, ischaemic heart disease, antihypertensives, nephropaties, aliskiren
Abstract: The renin angiotensin aldosterone system (RAAS) inhibitors induce an incomplete blockade of the system at different steps. Recently, the dual RAAS therapy is emerging in clinical practice, although there is a lack of evidence on safety and efficacy for this combination in several cardiovascular diseases. In this review, we evaluated the advantages and disadvantages of dual RAAS blockade in hypertension, proteinuric renal disease, heart failure and ischaemic heart disease. The role of DRIs in combination with ACEI or ARBs is promising, but still needs further studies. On the basis of the clinical outcomes and safety data the recommendations guidelines have not confirmed indications to dual RAAS blockade in essential hypertension treatment, heart failure and ischemic heart disease. Only proteinuric nephropaties and resistant hypertension may represent possible indications to dual RAAS blockade. Actually, rational combinations of either an ACEI or ARB or DRI with other classes of antihypertensives offer best solutions.
Export Options
About this article
Cite this article as:
Veglio Franco, Puglisi Elisabetta, Milan Alberto and Mulatero Paolo, Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436566
DOI https://dx.doi.org/10.2174/138161212799436566 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Development of Improved Factor VIII Molecules and New Gene Transfer Approaches for Hemophilia A
Current Gene Therapy Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Phenolic Content in Traditionally Processed Erythrina indica L. Seeds: Antioxidant Potential and Type II Diabetes Related Functionality
Current Nutrition & Food Science A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry Iron Overload and Glucose Metabolism in Subjects with β-thalassaemia Major : An Overview
Current Diabetes Reviews Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Pathophysiology of Arterial Hypertension: Insights from Pediatric Studies
Current Pediatric Reviews Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry The Use of Carvedilol in Pediatric Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Role of Ca2+-Sensitive K+ Currents in Controlling Ventricular Repolarization: Possible Implications for Future Antiarrhytmic Drug Therapy
Current Medicinal Chemistry Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Insulin and Endothelial Function: Physiological Environment Defines Effect on Atherosclerotic Risk
Current Diabetes Reviews Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers Thromboxane A<sub>2</sub> Receptor Polymorphism in Association with Cerebral Infarction and its Regulation on Platelet Function
Current Neurovascular Research